Natural killer cell treatment after a half-matched stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This early trial studies adding special immune cells called “natural killer cells” after a half-matched stem cell transplant for AML or MDS. The goal is to see if this approach improves outcomes and safety when there is no fully matched donor available.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are over 18 years old and have AML or MDS (not APL).
- You do not have a fully matched (HLA-matched) donor, but you do have a half-matched (haploidentical) relative who can donate.
- Your transplant team believes your organs are strong enough and there are no major reasons you cannot have a half-matched transplant.
- A blood test must not show very strong donor-specific anti-HLA antibodies (strong immune antibodies against the donor).
- You are not pregnant, and you would not need extra immune-suppressing medicines beyond standard GvHD prevention.
- Your donor is over 18, not pregnant, and can safely donate through an apheresis process.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new way to prevent leukemia from returning after a half-matched stem cell transplant. It uses specially activated natural killer cells to attack remaining cancer cells. This may help people with high-risk or relapsed AML who have few other options.
This trial tests an additional immune therapy made from donor natural killer (NK) cells given around the time of a special stem cell transplant for children and young adults with high-risk acute myeloid leukemia (AML). It aims to help prevent the leukemia from coming back or not responding after transplant.
This trial tests donated “natural killer (NK) cells,” a type of immune cell, in children and young adults with AML that has come back or did not respond to treatment. It mainly looks at safety and also studies whether the treatment can help control the leukemia.
This trial tests whether giving specially trained natural killer (NK) cells after a stem cell transplant can help prevent relapse in people with high-risk blood cancers like AML, MDS, or MDS/MPN. You receive one infusion of these cells about a week after your transplant.
This trial tests whether giving donor natural killer (NK) cells after a stem cell transplant can help prevent leukemia from coming back. It is for people aged 14-25 with certain hard-to-treat leukemias who are already getting a stem cell transplant from a related donor.
This study tests an “immune cell therapy” made from a family donor to help children and young adults with AML stay in remission after chemotherapy. It may help reduce the chance that AML comes back, but eligibility depends on remission status, donor suitability, and avoiding certain infections or liver issues.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.